GSH-targeted nanosponges increase doxorubicin-induced toxicity "in vitro" and "in vivo" in cancer cells with high antioxidant defenses

Free Radical Biology and Medicine

Volumn 97, Issue , 2016, Pages 24-37

  Daga, Martina ^a   Ulllio, Chiara ^a   Argenziano, Monica ^a   Dianzani, Chiara ^a   Cavalli, Roberta ^a   Trotta, Francesco ^a   Ferretti, Carlo ^a   Zara, Gian Paolo ^a   Gigliotti, Casimiro L ^b   Ciamporcero, Eric S ^a   Pettazzoni, Piergiorgio ^a   Corti, Denise ^c   Pizzimenti, Stefania ^a   Barrera, Giuseppina ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Doxorubicin; GSH targeted nanosponges; Prostate and colon cancer cells; Toxic effects

Indexed keywords

CYCLODEXTRIN DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLUTATHIONE DERIVATIVE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NANOCARRIER; NANOSPONGE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ANTIOXIDANT; GLUTATHIONE; NANOMATERIAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CARDIOTOXICITY; CELL CYCLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CIRCULATION TIME; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA DENATURATION; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURFACE CHARGE; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; MICE; NANOSTRUCTURES; NEOPLASMS; OXIDATIVE STRESS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971613914     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.05.009     Document Type: Article

References (37)

1. J. Wang, and J. Yi Cancer cell killing via ROS: to increase or decrease, that is the question Cancer Biol. Ther. 7 2008 1875 1884
2. H. Pelicano, D. Carney, and P. Huang ROS stress in cancer cells and therapeutic implications Drug Resist. Updat. 7 2004 97 110
3. J.P. Fruehauf, and F.L. Meyskens Jr. Reactive oxygen species: a breath of life or death? Clin. Cancer Res. 13 2007 789 794
4. C.M. Cabello, W.B. Bair 3rd, and G.T. Wondrak Experimental therapeutics: targeting the redox Achilles heel of cancer Curr. Opin. Investig. Drugs 8 2007 1022 1037
5. G. Barrera Oxidative stress and lipid peroxidation products in cancer progression and therapy ISRN Oncol. 2012 2012 137289
6. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8 2009 579 591
7. N. Traverso, R. Ricciarelli, M. Nitti, B. Marengo, A.L. Furfaro, M.A. Pronzato, U.M. Marinari, and C. Domenicotti Role of glutathione in cancer progression and chemoresistance Oxid. Med. Cell. Longev. 2013 972913
8. S.C. Lu Glutathione synthesis Biochim. Biophys. Acta 1830 2013 3143 3153
9. F.Q. Schafer, and G.R. Buettner Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple Free Radic. Biol. Med. 30 2001 1191 1212
10. R. Cheng, F. Feng, F. Meng, C. Deng, J. Feijen, and Z. Zhong Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery J. Control Release 152 2011 2 12
11. M. Takada, Y. Nakagawa, and M. Yamamoto Biochemical and genetic analyses of a novel gamma-cyclodextrin glucanotransferase from an alkalophilic Bacillus clarkii 7364 J. Biochem. 133 2003 317 324
12. J. Szejtli Introduction and general overview of cyclodextrin chemistry Chem. Rev. 98 1998 1743 1754
13. F. Trotta, M. Zanetti, and R. Cavalli Cyclodextrin-based nanosponges as drug carriers Beilstein J. Org. Chem. 8 2012 2091 2099
14. R. Minelli, R. Cavalli, L. Ellis, P. Pettazzoni, F. Trotta, E. Ciamporcero, G. Barrera, R. Fantozzi, C. Dianzani, and R. Pili Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells Eur. J. Pharm. Sci. 47 2012 686 694
15. R. Cavalli, F. Trotta, and W. Tumiatti Cyclodextrin-based nanosponges for drug delivery J. Incl. Phenom. 56 2006 209 213
16. R. Namgung, Y. Mi Lee, J. Kim, Y. Jang, B.H. Lee, I.S. Kim, P. Sokkar, Y.M. Rhee, A.S. Hoffman, and W.J. Kim Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy Nat. Commun. 5 2014 3702 10.1038/ncomms4702
17. C.L. Gigliotti, R. Minelli, R. Cavalli, S. Occhipinti, G. Barrera, S. Pizzimenti, G. Cappellano, E. Boggio, L. Conti, R. Fantozzi, M. Giovarelli, F. Trotta, U. Dianzani, and C. Dianzani In vitro and in vivo Therapeutic evaluation of camptothecin-encapsulated β-cyclodextrin nanosponges in prostate cancer J Biomed. Nanotechnol. 12 2016 114 127
18. F. Trotta, F. Caldera, C. Dianzani, M. Argenziano, G. Barrera, and R. Cavalli New glutathione bio-responsive cyclodextrin nanosponges ChemPlusChem 2016 10.1002/cplu.201500531
19. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229
20. G.L. Ellman Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
21. P.W. Sylvester Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability Methods Mol. Biol. 716 2011 157 168
22. B.B. Zhou, and S.J. Elledge The DNA damage response: putting checkpoints in perspective Nature 408 2000 433 439
23. G.A. Husseini, K.L. O'Neill, and W.G. Pitt The comet assay to determine the mode of cell death for the ultrasonic delivery of doxorubicin to human leukemia (HL-60 cells) from Pluronic P105 micelles Technol. Cancer Res. Treat. 4 2005 707 711
24. A. Fundarò, R. Cavalli, A. Bargoni, D. Vighetto, G.P. Zara, and M.R. Gasco Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats Pharmacol. Res. 42 2000 337 343
25. F. Yang, S.S. Teves, C.J. Kemp, S. Henikoff, and D.N.A. Doxorubicin torsion, and chromatin dynamics Biochim. Biophys. Acta 84-89 1845 2013
26. B.T. Kalet, M.B. McBryde, J.M. Espinosa, and T.H. Koch Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism J. Med. Chem. 50 2007 4493 4500
27. L.F. Liu, T.C. Rowe, L. Yang, K.M. Tewey, and G.L. Chen Cleavage of DNA by mammalian DNA topoisomerase II J. Biol. Chem. 258 1983 15365 15370
28. D.W. Fairbairn, P.L. Olive, and K.L. O'Neill The comet assay: a comprehensive review Mutat. Res. 339 1995 37 59
29. B. Vogelstein, D.M. Pardoll, and D.S. Coffey Supercoiled loops and eucaryotic DNA replicaton Cell 22 1980 79 85
30. V. Toncheva, E. Schacht, S.Y. Ng, J. Barr, and J. Heller Use of block copolymers of poly(ortho esters) and poly (ethylene glycol) micellar carriers as potential tumour targeting systems J. Drug Target. 11 2003 345 353
31. J. Liu, F. Zeng, and C. Allen Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent J. Control. Release 103 2005 481 497
32. Y. Matsumura, T. Hamaguchi, T. Ura, K. Muro, Y. Yamada, Y. Shimada, K. Shirao, T. Okusaka, H. Ueno, M. Ikeda, and N. Watanabe Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br. J. Cancer 91 2004 1775 1781
33. L.P. Swift, A. Rephaeli, A. Nudelman, D.R. Phillips, and S.M. Cutts Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death Cancer Res. 66 2006 4863 4871
34. A.K. Larsen, A.E. Escargueil, and A. Skladanowski From DNA damage to G2 arrest: the many roles of topoisomerase II Prog. Cell Cycle Res. 5 2003 295 300
35. K. Greish Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting Methods Mol Biol. 624 2010 25 37
36. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Deliv. Rev. 65 2013 71 79
37. G. Takemura, and H. Fujiwara Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management Prog. Cardiovasc. Dis. 49 2007 330 352